Market LIVE
Published markets; coverage varies by country
Product profile · United States

LUMISIGHT

 ·  Patent Litigation & Settlement History ↓

IngredientPEGULICIANINE ACETATE
Application typeNDA
Application214511
Product001
Dosage formPOWDER
RouteINTRAVENOUS
StrengthEQ 39MG BASE/VIAL
Approval date2024-04-17
Marketing statusPrescription
Status event—
ApplicantLUMICELL
Product source

Current GenericRadar decision

Year2024
SelectionEXCLUDED
ReviewFINAL
Anchor typeAPPROVAL_DATE
Anchor date2024-04-17
Patent anchor2034-09-14
Exclusivity anchor2029-04-17
Protection date2034-09-14
First Final ANDA—
Status event—

GNR judgment: EXCLUDED. Reference year: 2024. Anchor type: APPROVAL_DATE. Patent anchor: 2034-09-14. Exclusivity anchor: 2029-04-17. Anchor date: 2024-04-17. Patent tail: no. Exclusivity tail: no. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
115923962030-09-01DS —NYU
| B1C03 issued-claim review2026-10-15: U
———
115923962030-09-01ORANGE_BOOK —NYU
English description not available.
———
91554712031-10-12U U-3890NYU
| B1C03 issued-claim review2026-10-15: U
———
91554712031-10-12ORANGE_BOOK U-3890NYU
English description not available.
———
102857592031-12-08U U-3890NYU
| B1C03 issued-claim review2026-10-15: U
———
102857592031-12-08ORANGE_BOOK U-3890NYU
English description not available.
———
90329652031-12-08U U-3890NNU
| B1C03 issued-claim review2026-10-15: U
———
90329652031-12-08ORANGE_BOOK U-3890NNU
English description not available.
———
95328352031-12-08U U-3890NYU
| B1C03 issued-claim review2026-10-15: U
———
95328352031-12-08ORANGE_BOOK U-3890NYU
English description not available.
———
97635772034-09-14DS/DP/U U-3890YNTRUE_DS
| B1C03 issued-claim review2026-10-15: TRUE_DS
———
97635772034-09-14ORANGE_BOOK U-3890YNTRUE_DS
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2024-04-172029-04-17English description not available.YY2029-04-17—Source
NCE2024-04-172029-04-17English description not available.YY2029-04-17
NCE
Full coverage date: 2029-04-17
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (8)
TypeDateRoleBasisSource
PATENT2030-09-01HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2031-10-12HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2031-12-08HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2031-12-08HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2031-12-08HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2034-09-14HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_STATUS2024-04-17TERMINAL_STATUSEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.